Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Research & Development came in at $7.0 million in Q1 2026, down 33.34% YoY from $10.5 million in Q1 2025, and up 11.23% on a QoQ basis from $6.3 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Research & Development (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 8 years of Research & Development data on file, last reported at $7.0 million in Q1 2026.
- Quarterly Research & Development fell 33.34% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.1 million (down 37.74% YoY) and the FY2025 annual result came in at $33.6 million, down 34.6% from the prior year.
- Research & Development advanced to $7.0 million in Q1 2026, from $6.3 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $17.8 million in Q1 2022 to a low of $6.3 million in Q4 2025.
- A 5-year average of $12.7 million and a median of $13.2 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development grew 4.65% — and 2025, when it sank 48.8%.
- Tracing BDTX's Research & Development over 5 years: stood at $14.6 million in 2022, then gained by 4.65% to $15.3 million in 2023, then decreased by 19.57% to $12.3 million in 2024, then slumped by 48.8% to $6.3 million in 2025, then advanced by 11.23% to $7.0 million in 2026.
- The last three Research & Development figures came in at $7.0 million (Q1 2026), $6.3 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.05 Bn | 131.20 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.49 Bn | 60.31 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.79 Bn | 51.65 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.14 Bn | 37.05 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.71 Bn | 9.32 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.51 Bn | - | 97.90 Mn |
| 10 | Black Diamond Therapeutics | 125.35 Mn | 14.84 Mn | - | 7.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.39 Mn |
| Mar 31, 2026 | 7.00 Mn |
| Dec 31, 2025 | 6.30 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 9.32 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | 12.91 Mn |
| Jun 30, 2024 | 12.56 Mn |
| Mar 31, 2024 | 13.55 Mn |
| Dec 31, 2023 | 15.29 Mn |
| Sep 30, 2023 | 16.15 Mn |
| Jun 30, 2023 | 13.15 Mn |
| Mar 31, 2023 | 14.75 Mn |
| Dec 31, 2022 | 14.61 Mn |
| Sep 30, 2022 | 15.85 Mn |
| Jun 30, 2022 | 16.20 Mn |
| Mar 31, 2022 | 17.79 Mn |
| Dec 31, 2021 | 19.66 Mn |
| Sep 30, 2021 | 27.63 Mn |